BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22176869)

  • 1. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.
    Yi JH; Thongprasert S; Lee J; Doval DC; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Eur J Cancer; 2012 Jan; 48(2):196-201. PubMed ID: 22176869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
    Reni M; Cereda S; Milella M; Novarino A; Passardi A; Mambrini A; Di Lucca G; Aprile G; Belli C; Danova M; Bergamo F; Franceschi E; Fugazza C; Ceraulo D; Villa E
    Eur J Cancer; 2013 Nov; 49(17):3609-15. PubMed ID: 23899530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
    Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
    Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
    Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
    J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.
    He Z; Guo G; Zhang C; Li X; Fu W; Jin J; Zhang X; Zhou L
    Chin Med J (Engl); 2014; 127(8):1450-3. PubMed ID: 24762587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
    Li XS; Song Y; Gong K; Zhang Q; Yu W; Song G; Zhao Z; Zhang Z; Wang G; Zhou LQ; He ZS; Jin J
    Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(5):375-7. PubMed ID: 20450612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
    Faivre S; Raymond E; Boucher E; Douillard J; Lim HY; Kim JS; Zappa M; Lanzalone S; Lin X; Deprimo S; Harmon C; Ruiz-Garcia A; Lechuga MJ; Cheng AL
    Lancet Oncol; 2009 Aug; 10(8):794-800. PubMed ID: 19586800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
    J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
    Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
    J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
    Novello S; Camps C; Grossi F; Mazieres J; Abrey L; Vernejoux JM; Thall A; Patyna S; Usari T; Wang Z; Chao RC; Scagliotti G
    J Thorac Oncol; 2011 Jul; 6(7):1260-6. PubMed ID: 21610524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
    Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
    Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
    O'Reilly EM; Niedzwiecki D; Hall M; Hollis D; Bekaii-Saab T; Pluard T; Douglas K; Abou-Alfa GK; Kindler HL; Schilsky RL; Goldberg RM;
    Oncologist; 2010; 15(12):1310-9. PubMed ID: 21148613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.